Century Therapeutics to Present iPSC-Derived CNTY-813 (Featuring Allo-Evasion™ 5.0) for Type 1 Diabetes at ADA 86th Scientific Sessions

Benzinga USA

Overview

Century Therapeutics is scheduled to deliver an oral presentation on its innovative iPSC-derived islet cell replacement therapy, CNTY-813, for Type 1 diabetes at the American Diabetes Association (ADA) 86th Scientific Sessions on June 5, 2026. This therapy incorporates the company’s proprietary Allo-Evasion™ 5.0 technology, designed to circumvent immune rejection, highlighting its potential as an off-the-shelf cellular therapeutic. The presentation underscores Century Therapeutics’ commitment to providing long-term treatment solutions for Type 1 diabetes patients and raises expectations for its future clinical development and market introduction.

In Depth

Key Findings

Century Therapeutics announced that it will make a significant oral presentation on its pioneering iPSC-derived islet cell replacement therapy, CNTY-813, for the treatment of Type 1 diabetes at the American Diabetes Association (ADA) 86th Scientific Sessions on June 5, 2026. The presentation will underscore the advanced nature of CNTY-813, which is engineered with the company’s proprietary Allo-Evasion™ 5.0 technology designed to effectively evade immune rejection. This technology significantly broadens the potential of CNTY-813 as an off-the-shelf cellular therapeutic.

Technical and Clinical Details

CNTY-813 aims to restore lost insulin-producing function in Type 1 diabetes patients using islet cells differentiated from induced pluripotent stem cells (iPSCs). Central to this therapy is Century Therapeutics’ Allo-Evasion™ 5.0 platform, which combines multiple gene-editing strategies, including modification of major histocompatibility complex (MHC) genes and introduction of immune checkpoint molecules, to prevent donor cells from being attacked by the host’s immune system. This approach is expected to enable long-term cell engraftment and function with minimal or no immunosuppressive drugs. The off-the-shelf nature of the therapy eliminates the need for patient-specific manufacturing, enhancing treatment access and scalability.

Background and Industry Context

Type 1 diabetes is a chronic autoimmune disease where the body’s insulin-producing pancreatic cells are destroyed, requiring lifelong insulin replacement therapy. While existing islet transplantation is effective, it is hampered by donor scarcity and the necessity for lifelong immunosuppression. iPSC-derived islet cell therapy holds promise as a solution to donor shortages, but immune rejection remains a significant hurdle. Century Therapeutics’ Allo-Evasion™ 5.0 technology represents a cutting-edge approach to resolving this immune rejection problem, potentially revolutionizing Type 1 diabetes treatment. This marks a crucial step toward realizing universal donor cell therapies in regenerative medicine.

Future Outlook

The presentation of CNTY-813 at the ADA Scientific Sessions will be a major focal point for the scientific community and investors. If the Allo-Evasion™ 5.0 technology is demonstrated to function successfully in a clinical setting, CNTY-813 could become a new standard of care for Type 1 diabetes patients. Century Therapeutics aims to accelerate this groundbreaking therapy into clinical trials and ultimately provide hope for many patients to achieve insulin independence. This advancement showcases the broad potential of iPSC-derived cell therapies and is poised to have a significant impact on the future of regenerative medicine.